SANA · Sana Biotechnology, Inc.
$3.11
+0.48% last session
End-of-day data · close of 2026-09-11
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-5.6
Dividend yield
—
Beta
2.13
Avg volume
3M
Employees
0K
Daily Change %
0.48%
5 Days Change
-17.66%
10 Days Change
-18.09%
30 Days Change
-16.36%
60 Days Change
-17.66%
Month to Day Change
-17.23%
Year to Day Change
-22.11%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SANA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-14
Latest call per bank · past 12 months
Bank of America
Buy$6.00
+94.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | Bank of America | Maintains | Buy | $7.00 → $6.00 |
| 2026-04-14 | Wedbush | Maintains | Outperform | $6.00 → $7.00 |
| 2026-03-04 | HC Wainwright & Co. | Maintains | Buy | $9.00 → $7.00 |
| 2026-01-06 | Bank of America | Maintains | Buy | $6.00 → $7.00 |
| 2025-11-07 | Wedbush | Maintains | Outperform | $5.00 → $6.00 |
| 2025-11-07 | HC Wainwright & Co. | Maintains | Buy | $11.00 → $9.00 |
| 2025-10-30 | Citizens | Maintains | Market Outperform | $5.00 → $8.00 |
| 2025-09-24 | Wedbush | Initiates | Outperform | $0.00 → $5.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 35 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 13.5% below the 50-day MA ($3.59).
- Price vs 200-day MA: Trading 16.1% below the 200-day MA ($3.70).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.12) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($2.68) and high ($5.92).
SANA Price Chart
Loading chart for SANA…
Fundamentals
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.